CareDx, Inc. announced the completion of two significant transactions on June 30, 2026, and July 1, 2026, respectively. The company sold its Lab Products business, including IVD PCR and NGS kits for HLA typing and monitoring assays, to Eurobio Scientific S.A. for $171.7 million in cash, subject to customary adjustments. Concurrently, CareDx acquired Naveris, Inc., a company specializing in blood-based tests for viral-mediated cancers, for an initial payment of $161.8 million in cash. The Naveris acquisition includes potential additional cash consideration of up to $100.0 million contingent on achieving specified revenue milestones for fiscal years 2026 and 2027. Naveris's lead product, NavDx, is a Medicare-covered test for HPV-associated head and neck and anal cancers, detecting and monitoring molecular residual disease (MRD). Naveris generated approximately $35 million in revenue in 2025, more than doubling year-over-year, and has an ADLT Medicare reimbursement rate of $1,800 per test. These transactions are expected to sharpen CareDx's focus on its core U.S. Precision Medicine Testing Services and Patient and Digital Solutions, while expanding its addressable market to over $12 billion. Naveris will be included in CareDx's consolidated financial results starting in the third quarter of 2026. Financial statements and pro forma financial information for the Naveris acquisition will be filed by amendment within 71 calendar days.